SAM
NBIX icon

Smartleaf Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Smartleaf Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76.5K Sell
594
-84
-12% -$11.1K ﹤0.01% 1245
2025
Q4 		$95.6K Buy
678
+254
+60% +$36.8K ﹤0.01% 1212
2025
Q3 		$59.5K Buy
424
+224
+112% +$30.4K ﹤0.01% 1310
2025
Q2 		$25.1K Sell
200
-206
-51% -$23.6K ﹤0.01% 1459
2025
Q1 		$45.9K Sell
406
-132
-25% -$16.7K ﹤0.01% 1193
2024
Q4 		$73.7K Buy
538
+146
+37% +$18.1K 0.01% 989
2024
Q3 		$45.1K Buy
392
+251
+178% +$34.4K 0.01% 956
2024
Q2 		$18.9K Buy
141
+94
+200% +$12.9K ﹤0.01% 1058
2024
Q1 		$6.48K Buy
47
+44
+1,467% +$6.01K ﹤0.01% 1135
2023
Q4 		$0 Buy
+3
New +$345 ﹤0.01% 1201

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Smartleaf Asset Management's NBIX Position: Q1 2026 in Review

Smartleaf Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 12% in Q1 2026, selling an estimated $11.1K and leaving 594 shares worth $76.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1245.

Smartleaf Asset Management first reported a position in NBIX in Q4 2023 and has held it in 10 quarters since. The position peaked at $95.6K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Smartleaf Asset Management held 594 shares of Neurocrine Biosciences worth $76.5K as of Q1 2026.
  • Smartleaf Asset Management sold 84 Neurocrine Biosciences shares in Q1 2026, an estimated $11.1K.
  • Neurocrine Biosciences made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #1245 holding.
  • Smartleaf Asset Management first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 10 quarters since.
  • Smartleaf Asset Management's Neurocrine Biosciences position peaked at $95.6K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.